GHS-R1a raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-12 and is reviewed periodically as new material appears.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
=== Cell cycle === TGF-β plays a crucial role in the regulation of the cell cycle by blocking progress through G1 phase. TGF-β causes synthesis of p15 and p21 proteins, which block the cyclin:CDK complex responsible for retinoblastoma protein (Rb) phosphorylation. Thus, TGF-β blocks advancement through the G1 phase of the cycle. In doing so, TGF-β suppresses expression of c-myc, a gene which is involved in G1 cell cycle progression.
Despite his advanced age and having stepped down as prime minister, Mahathir remains active on the international stage, frequently travelling, delivering speeches, and continuing to voice his views and influence both domestically and globally. Shortly after Malaysia entered its first movement control order in March 2020, Mahathir underwent self-quarantine at home after having close contact with Bandar Kuching MP Kelvin Yii Lee Wuen, who later tested positive for COVID-19. He formed the Homeland Fighter's Party (PEJUANG) in August 2020. Four other MPs joined the new party, including Mahathir's son Mukhriz. The party was registered in July 2021. In August 2021, Mahathir and other MPs protested in Merdeka Square, calling for Muhyiddin's resignation over the government's response to the COVID-19 pandemic, after being blocked from entering parliament by police. In April 2022, UMNO president Ahmad Zahid Hamidi filed a defamation lawsuit against Mahathir. In June 2022, Mahathir made irrendentist comments by stating that Singapore and the Riau Islands of Indonesia was once owned by Johor, and argued the state should claim them as part of Malaysia. In September 2022, Mahathir said he was open to becoming the prime minister for a third time if there were no other suitable candidates. Having previously said he would not defend his Langkawi parliamentary seat, he announced he would contest the 2022 general election. In the election on 19 November, Mahathir lost his seat and election deposit, marking his first defeat in 53 years.
Star anise is the major source of the chemical compound shikimic acid, a primary precursor in the pharmaceutical synthesis of the anti-influenza drug oseltamivir (Tamiflu). An industrial method for the production of shikimic acid using fermentation of E. coli bacteria was discovered in 2005, and applied in the 2009 swine flu pandemic to address Tamiflu shortages, eventually reversing price increases for star anise as a raw material of shikimic acid. As of 2018, fermentation of E. coli was the manufacturing process of choice to produce shikimic acid for synthesis of Tamiflu.
== Side effects == Protriptyline shares side effects common to all TCAs. The most frequent of these are dry mouth, constipation, urinary retention, increased heart rate, sedation, irritability, decreased coordination, anxiety, blood disorders, confusion, decreased libido, dizziness, flushing, headache, impotence, insomnia, low blood pressure, nightmares, rapid or irregular heartbeat, rash, seizures, sensitivity to sunlight, stomach and intestinal problems. Other more complicated side effects include; chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling; sudden numbness or weakness, especially on one side of the body; sudden headache, confusion, problems with vision, speech, or balance; hallucinations, or seizure (convulsions); easy bruising or bleeding, unusual weakness; restless muscle movements in your eyes, tongue, jaw, or neck; urinating less than usual or not at all; extreme thirst with headache, nausea, vomiting, and weakness; or feeling light-headed or fainting. Dry mouth, if severe to the point of causing difficulty speaking or swallowing, may be managed by dosage reduction or temporary discontinuation of the drug. Patients may also chew sugarless gum or suck on sugarless candy in order to increase the flow of saliva. Some artificial saliva products may give temporary relief. Men with prostate enlargement who take protriptyline may be especially likely to have problems with urinary retention. Symptoms include having difficulty starting a urine flow and more difficulty than usual passing urine.
Sources: en.wikipedia.org
The H-type pseudoknot core of mini-NAD⁺-II aptamers is structurally analogous to that of the preQ1-I riboswitch class, one of the smallest known natural riboswitch aptamers. Both classes represent the shortest known natural RNA aptamers, yet achieve high ligand-binding specificity. This structural similarity suggests that simple H-type pseudoknots may function as versatile scaffolds for constructing ligand-binding aptamers, either naturally or synthetically. Biochemical analysis using in-line probing confirmed that mini-NAD⁺-II RNAs bind both NAD⁺ and NMN, with strong preference for NMN. Biochemical analysis using in-line probing confirmed that mini-NAD⁺-II RNAs bind both NAD⁺ and NMN, with strong preference for NMN. Mini-NAD⁺-II aptamers discriminate more strongly between NMN and NAD⁺ than the larger P1a containing aptamers, likely because they lack the conserved adenosines flanking P1a that make non-specific contacts with the adenosine moiety of NAD⁺. Gene Regulation NAD⁺-II and mini-NAD⁺-II riboswitches are predicted to function as translational "OFF" switches: when NAD⁺ or NMN concentrations are sufficiently high, the riboswitch ligand-bound conformation sequesters the Shine-Dalgarno sequence within a pseudoknot, preventing ribosome binding and repressing translation of the downstream gene. The downstream genes regulated by NAD⁺-II and mini-NAD⁺-II riboswitches include:
The COVID-19 Immunity Task Force (CITF) was one of the Government of Canada's early efforts to track the 2020 coronavirus pandemic. An external, dedicated secretariat was established in order to maximize the efficiency of the CITF's work. The group terminated its mandate on March 31, 2024. The group terminated its mandate on March 31, 2024. During the four-year period, the CITF provided several purposes and uses for the general Canadian population. The CITF was to use a serology "to survey representative samples of the population for the presence of antibodies to the virus". Trudeau's press release on 23 April 2020, on the initiation of the CCITF listed several goals it would help to achieve notably that it would: establish priorities and oversee the coordination of a series of country-wide blood test surveys that will tell us how widely the virus has spread in Canada and provide reliable estimates of potential immunity and vulnerabilities in Canadian populations. Canada's government funded more than $1 billion for research into how to combat COVID-19 through the CITF.
=== Chemical === The chemistry of nobelium is incompletely characterized and is known only in aqueous solution, in which it can take on the +3 or +2 oxidation states, the latter being more stable. It was largely expected before the discovery of nobelium that in solution, it would behave like the other actinides, with the trivalent state being predominant; however, Seaborg predicted in 1949 that the +2 state would also be relatively stable for nobelium, as the No2+ ion would have the ground-state electron configuration [Rn]5f14, including the stable filled 5f14 shell. It took nineteen years before this prediction was confirmed. In 1967, experiments were conducted to compare nobelium's chemical behavior to that of terbium, californium, and fermium. All four elements were reacted with chlorine and the resulting chlorides were deposited along a tube, along which they were carried by a gas. It was found that the nobelium chloride produced was strongly adsorbed on solid surfaces, proving that it was not very volatile, like the chlorides of the other three investigated elements. However, both NoCl2 and NoCl3 were expected to exhibit nonvolatile behavior and hence this experiment was inconclusive as to what the preferred oxidation state of nobelium was. Determination of nobelium's favoring of the +2 state had to wait until the next year, when cation-exchange chromatography and coprecipitation experiments were carried out on around fifty thousand 255No atoms, finding that it behaved differently from the other actinides and more like the divalent alkaline earth metals.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.